Wen Tian, Stanley G Rockson, Xinguo Jiang, Jeanna Kim, Adrian Begaye, Eric M Shuffle, Allen B Tu, Matthew Cribb, Zhanna Nepiyushchikh, Abdullah H Feroze, Roham T Zamanian, Gundeep S Dhillon, Norbert F Voelkel, Marc Peters-Golden, Jan Kitajewski, J Brandon Dixon, Mark R Nicolls
Acquired lymphedema is a cancer sequela and a global health problem currently lacking pharmacologic therapy. We have previously demonstrated that ketoprofen, an anti-inflammatory agent with dual 5-lipoxygenase and cyclooxygenase inhibitory properties, effectively reverses histopathology in experimental lymphedema. We show that the therapeutic benefit of ketoprofen is specifically attributable to its inhibition of the 5-lipoxygenase metabolite leukotriene B4 (LTB4). LTB4 antagonism reversed edema, improved lymphatic function, and restored lymphatic architecture in the murine tail model of lymphedema...
May 10, 2017: Science Translational Medicine